Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

482
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

499
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
499
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

325
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
325
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

506
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
506
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

1.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain Natriuretic Peptide mediates the prognostic role of renal function toward 10-year cardiovascular mortality in patients with Acute Coronary Syndrome: the HHF study (2006-2016).

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese·2017
Same author

Detecting human coronary inflammation by imaging perivascular fat.

Science translational medicine·2017
Same author

Assessment of left ventricular function and geometry in hypertensive patients: Novel approaches in every day clinical practice.

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese·2017
Same author

Modern management of hypertensive emergencies and urgencies: Do we need more technology, paramedics, or physicians?

Journal of clinical hypertension (Greenwich, Conn.)·2017
Same author

Macrovascular function indices for the prediction of diabetic retinopathy development in patients with type 2 diabetes.

European journal of preventive cardiology·2017
Same author

Data Sharing: A New Editorial Initiative of the International Committee of Medical Journal Editors. Implications for the Editors' Network.

Acta Cardiologica Sinica·2017

Related Experiment Video

Updated: Feb 24, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

11.9K

Statins in Aortic Stenosis.

Karl Norrington1, Emmanuel Androulakis2, Evangelos Oikonomou3

  • 1Cardiology Department, Barts Health NHS Trust, London. United Kingdom.

Current Pharmaceutical Design
|August 18, 2017
PubMed
Summary

Statins do not prevent the progression of calcific aortic stenosis (AS). Novel therapies targeting lipoprotein(a) (Lp(a)) show promise for managing this common heart valve disease.

Keywords:
Aortic StenosisHMG-CoA ReductaseLipidsStatinsValvular Heart Disease

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.4K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Related Experiment Videos

Last Updated: Feb 24, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

11.9K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.4K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Area of Science:

  • Cardiology
  • Vascular Biology
  • Pharmacology

Background:

  • Calcific aortic stenosis (AS) is a prevalent valvular heart disease in Western countries, characterized by progressive obstruction requiring valve replacement.
  • Statins, widely used for coronary artery disease, were investigated for their potential to slow AS progression.
  • Previous studies yielded conflicting results regarding statin efficacy in AS.

Purpose of the Study:

  • To evaluate the effectiveness of statin therapy in preventing the progression of calcific aortic stenosis.
  • To explore emerging therapeutic targets for AS, particularly lipoprotein(a) (Lp(a)).

Main Methods:

  • Review of evidence from animal studies, retrospective analyses, and non-randomized prospective trials.
  • Analysis of outcomes from three major randomized controlled trials (RCTs) of statin therapy in AS.
  • Consideration of recent research on the role of lipoprotein(a) in AS pathogenesis.

Main Results:

  • Three major RCTs demonstrated no significant benefit of statin therapy on AS progression or clinical outcomes.
  • Statin therapy is not recommended solely for preventing AS progression without other indications for lipid-lowering.
  • Lipoprotein(a) (Lp(a)) has emerged as a critical factor in AS progression, independent of statin effects.

Conclusions:

  • Current evidence does not support the use of statins to prevent AS progression.
  • Targeted therapies aimed at reducing Lp(a) levels, such as PCSK9 inhibitors and antisense oligonucleotides, represent a promising new avenue for AS management.